Compare Moderna, Inc. (MRNA) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ArcelorMittal SA — how do they compare? Moderna, Inc. trades at $136.28 (market cap $56.02B), while ArcelorMittal SA trades at $76.53 (market cap $58.51B). The key difference: Moderna, Inc. and ArcelorMittal SA are close in size by market cap, and ArcelorMittal SA pays a 0.78% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MT | |
|---|---|---|
Market Cap | $56.02B | $58.51B |
Sector | Health | Basic Materials |
52-Week High | $174.38 | $78.74 |
52-Week Low | $22.36 | $34.39 |
Enterprise Value | $52.17B | $68.08B |
Dividend Yield | — | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
ArcelorMittal (MT) trades at $77.15, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing year-over-year sales growth. Recent news highlights expansion in steel capacity and strategic partnerships, while facing headwinds from weak Chinese demand and geopolitical risks in Ukraine. Cash flow trends show a narrowing net outflow, improving from 2023 levels.
The outlook is cautiously optimistic, supported by analyst consensus and European demand improvements, but risks from industry cyclicality and input cost pressures remain. Investment appeal hinges on execution of growth initiatives and macroeconomic stability in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
